Rani Therapeutics Holdings Inc (RANI) — Titan Protect Analysis

RANI

Rani Therapeutics Holdings Inc

Healthcare · ·

$0.83

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$117M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.87

Based on estimated future earnings — lower means cheaper

Rev Growth

+893.0%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-240.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.00

+743% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes

https://www.ranitherapeutics.com

Country: United States Employees: 69 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.189

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0104

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.631

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-58.0%

Historical annualised return based on price data

Max Drawdown

-91.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$3.87

79% below the year high

52W Low

$0.39

114% above the year low

Avg Volume

1,150,226

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.27

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

11.09

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-488.2%

Profit from core operations before interest and tax

Free Cash Flow

$-3,383,000

Negative — the business is spending more than it generates

Revenue (TTM)

$3M

Total revenue over the last 12 months

Net Income

$-29,442,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$11.00

Target Median

$7.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go